ARHGDIB在恶性肿瘤中的研究进展  

Research progress of ARHGDIB in malignant tumors

作　　者：张婧萱 乔媛[1] 王婷婷 赵建国[1] 宝莹娜[1] ZHANG Jingxuan;QIAO Yuan;WANG Tingting;ZHAO Jianguo;BAO Yingna(Department of Radiotherapy,the Affiliated Hospital of Inner Mongolia Medical University,Inner Mongolia Autonomous Region,Hohhot010030,China)

机构地区：[1]内蒙古医科大学附属医院放疗科,内蒙古呼和浩特010030

出　　处：《中国医药导报》2024年第19期46-50,共5页China Medical Herald

基　　金：内蒙古自治区自然科学基金项目(2019MS08124);内蒙古自治区科技计划项目(2019GG150);内蒙古医科大学面上项目(YKD2021MS032)。

摘　　要：侵袭和转移是恶性肿瘤难以治疗的重要因素,ARHGDIB参与多种恶性肿瘤的侵袭和转移,是一类具有重要作用的转移抑制剂。本文阐述ARHGDIB通过调节Rho GTP酶参与多种信号通路,调控恶性肿瘤的侵袭和转移。ARHGDIB在膀胱癌、胃癌及白血病中主要通过Rac通路发挥作用,而在肺癌、肝癌和胰腺导管腺癌中,其对PI3K/PKB/Akt信号通路的调控较常见。ARHGDIB通过调控肿瘤微环境中的炎症反应抑制恶性肿瘤的转移,因此,其在不同恶性肿瘤中可通过调控不同信号通路发挥作用。Invasion and metastasis are important factors that make malignant tumors difficult to treat.ARHGDIB is involved in invasion and metastasis of various malignant tumors and is a class of important metastasis inhibitors.This article elaborates on involvement of ARHGDIB in multiple signaling pathways by regulating Rho GTPase,regulating invasion and metastasis of malignant tumors.ARHGDIB plays a role mainly through Rac pathway in bladder cancer,gastric cancer,and leukemia,while in lung cancer,liver cancer,and pancreatic ductal adenocarcinoma,its regulation of PI3K/PKB/Akt signaling pathway is more common.ARHGDIB inhibits metastasis of malignant tumors by regulating inflammatory response in tumor microenvironment.Therefore,it can play a role in different malignant tumors by regulating different signaling pathways.

关 键 词：ARHGDIB 恶性肿瘤 转移 Rho GTP酶 

分 类 号：R73[医药卫生—肿瘤]